AI-generated analysis. Always verify with the original filing.
Editas Medicine, Inc. reported Q4 and full year 2025 financial results with net loss of $5.6 million ($0.06 per share) for Q4 and $160.1 million ($1.80 per share) for the year, improved from prior year, alongside cash of $146.6 million funding into Q3 2027. Lead candidate EDIT-401 remains on track for IND/CTA submission by mid-2026 and first-in-human trial in HeFH patients with proof-of-concept data by year-end 2026.
Event Type
Disclosure
Mandatory
Variant
8-K
in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “Filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press release issued by the Company on March 9, 2026 * 104 Cover Page Interactive D
| Metric | Value | Basis |
|---|---|---|
| Collaboration and other research and development revenues | $24.7K | GAAP |
| Research and development expenses | $27.4K | GAAP |
| General and administrative expenses | $11.4K | GAAP |
| Net loss attributable to common stockholders | $-5.6K | GAAP |
| Net loss per share, basic and diluted | $-0.06 | GAAP |